-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Hold on Caris Life Sciences, Raises Price Target to $30

Benzinga·10/19/2026 13:03:05
Canaccord Genuity analyst Kyle Mikson maintains Caris Life Sciences (NASDAQ:CAI) with a Hold and raises the price target from $22 to $30.